Key Takeaways:
- FDA approved Artivion's AMDS Hybrid Prosthesis for acute aortic dissections
- The device cut 30-day mortality by 72% in the 93-patient PERSEVERE trial
- PMA approval removes IRB requirement, opening a $150 million annual US market
Back
Artivion wins FDA approval for AMDS, unlocking $150 million US market
Artivion Inc. received FDA premarket approval for its AMDS Hybrid Prosthesis, the first aortic arch remodeling device for acute DeBakey Type I aortic dissections, clearing the way for broader hospital adoption and access to an estimated $150 million annual US market.
"The PMA approval not only validates the enduring benefits shown in the PERSEVERE clinical data but also removes a barrier to broader adoption by eliminating the IRB requirement that came with the HDE," Pat Mackin, chairman, president and chief executive officer of Artivion, said.
The PMA — a higher regulatory bar requiring clinical evidence — replaces the Humanitarian Device Exemption under which AMDS had been available since its commercial introduction. Hospitals previously needed institutional review board approval to implant the device, a process that limited adoption. The approval covers acute DeBakey Type I aortic dissections with malperfusion, which account for about 60% of the roughly 6,000 US patients who present with the condition each year. Left untreated, mortality reaches about 1% per hour and as high as 50% within 48 hours.
The PERSEVERE trial enrolled 93 US patients and showed a 72% reduction in all-cause mortality at 30 days and a 54% reduction in major adverse events including stroke, renal failure requiring dialysis and myocardial infarction, compared with standard hemiarch repair. No distal anastomotic new entry tears occurred in the AMDS group, versus an estimated 45% rate in standard hemiarch procedures. Two-year follow-up data presented at the Society of Thoracic Surgeons meeting in February showed continued absence of DANE tears, stable aortic diameter and continued expansion of the true lumen across aortic zones 1 through 6, with no additional unanticipated aortic reoperations.
Competitive Positioning and Market Impact
The AMDS is deployed during standard ascending aorta replacement without adding technical complexity, preserving the native arch and enabling minimally invasive re-interventions if needed. Artivion, based in suburban Atlanta, has already built commercial infrastructure during its HDE launch and reported strong reordering momentum among existing accounts. The company also recently acquired the PMA-approved NEXUS system and is advancing its ARCEVO LSA clinical trial, positioning itself as a provider of a complete aortic arch solution.
Artivion shares are likely to benefit from the expanded addressable market and reduced adoption friction. The $150 million annual US opportunity represents a significant revenue driver for the company, which also markets aortic stent grafts, surgical sealants, On-X mechanical heart valves and implantable cardiac tissues. With the IRB barrier removed, hospitals can now treat eligible patients immediately, and analysts may revise revenue estimates upward as adoption accelerates across US institutions.
This article is for informational purposes only and does not constitute investment advice.
